Search clinical trials for: bevacizumab and trabectedin

Total 273212 results

Seoul St. Mary's Hospital

Unknown

Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy

Diabetes Complications

Korea, Republic of
Amsterdam UMC, location VUmc

Terminated

Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer

Toxicity

Netherlands
Federal University of São Paulo

Unknown

Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD

Macular Degeneration

Brazil
National Taiwan University Hospital

Unknown

Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation

Diabetic Retinopathy With Premacular Hemorrhage

Taiwan
Associacio catalana per a la recerca oncologica...
Hoffmann-La Roche

Unknown

XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Rectal Neoplasms | Locally Advanced Rectal Adenocarcinoma

Spain
Nanfang Hospital of Southern Medical University

Recruiting

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Colorectal Cancer Stage IV

China
ARCAGY/ GINECO GROUP

Active, not recruiting

PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . (NEOPEMBROV)

Ovarian Cancer Stage IV

France
Fudan University

Recruiting

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS Mutation | Cadonilimab

China
Sun Yat-sen University

Recruiting

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

Hepatocellular Carcinoma

China
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Astrocytoma of Brain

China
University Hospital, Ghent

Recruiting

Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema

Macular Edema | Retinal Neovascularization

Belgium
Asociación para Evitar la Ceguera en México

Terminated

Intravitreal Bevacizumab for Age-Related Macular Degeneration

Age Related Macular Degeneration

Mexico
Outlook Therapeutics, Inc.

Active, not recruiting

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders (NORSE SEVEN)

Age-Related Macular Degeneration | Diabetic Macular Edema | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | BRVO - Branch Retinal Vein Occlusion

United States
Northwell Health
Feinstein Institute for Medical Research; Hofstra North Shore

Suspended

Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma

Vestibular Schwannoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Agenus Inc.

Terminated

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Gliosarcoma | Recurrent Glioblastoma | Recurrent Adult Brain Tumor

United States
Outlook Therapeutics, Inc.

Completed

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Age-related Macular Degeneration | Diabetic Macular Edema | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | BRVO - Branch Retinal Vein Occlusion

United States
University of Colorado, Denver
Genentech, Inc.

Terminated

The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors

Radiation Necrosis

United States
Memorial Sloan Kettering Cancer Center
Columbia University; Genentech, Inc.; University of California, San Francisco

Completed

Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

Glioblastoma | Brain Cancer | Anaplastic Astrocytoma (AA) | Anaplastic Oligodendroglioma (AO) | MALIGNANT GLIOMA | Anaplastic Oligo-astrocytoma (AOA) | Anaplastic Mixed Gliomas | Malignant Glioma NOS

United States
Azienda Ospedaliero, Universitaria Pisana

Completed

Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer (CIRCUS)

Metastatic Colorectal Cancer

Italy
Centre Leon Berard
UMR-S Inserm 1036

Completed

Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab (AVECC)

Colorectal Cancer | Metastasis

France
Ronald Hoffman
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Terminated

Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis

Myelofibrosis

United States
Genentech, Inc.

Completed

A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer

Breast Cancer
Genentech, Inc.

Completed

A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Colorectal Cancer
Taiho Pharmaceutical Co., Ltd.

Completed

Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)

Colorectal Cancer

Japan
Indiana University
Genentech, Inc.

Completed

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

Neoplasms, Germ Cell and Embryonal

United States
National Cancer Institute (NCI)

Active, not recruiting

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Lynch Syndrome | Colon Mucinous Adenocarcinoma | Colon Signet Ring Cell Adenocarcinoma | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7

United States, Canada, Puerto Rico, Peru, South Africa
Genentech, Inc.

Completed

A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Metastatic Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

China
Hospices Civils de Lyon

Active, not recruiting

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer (BEVANEC)

Neuroendocrine Carcinomas

France
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Completed

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

Liver Cancer

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort (CORIMMUNO-BEVA)

COVID19 Pneumonia
University of California, San Diego

Completed

Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT)

United States
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects

Healthy

New Zealand
Genentech, Inc.

Withdrawn

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

Renal Cell Cancer
Neon Hospital
Ondokuz Mayıs University

Completed

The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

Diabetic Macular Edema
ARCAGY/ GINECO GROUP

Completed

First Line Metastatic Breast Cancer Treatment (ESMERALDA) (ESMERALDA)

Metastatic Breast Cancer

France
Children's Hospital Los Angeles

Temporarily not available

Use of Pan-Vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

Retinopathy of Prematurity

United States
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Malignant Pleural Effusion
Beijing Sanbo Brain Hospital

Suspended

Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)

Recurrent Glioblastoma

China
University Medical Center Groningen
Novartis

Completed

Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma (Everolimage)

Metastatic Renal Cell Carcinoma

Netherlands
University Medical Center Groningen
VHL Alliance

Completed

Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease (VHLimage)

Renal Cell Carcinoma | Von Hippel-Lindau Disease | Pheochromocytoma | Pancreatic Neuroendocrine Tumor | Hemangioblastoma

Netherlands
Pfizer

Completed

A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)

Healthy

United States
University Medical Center Groningen

Not yet recruiting

Safety and Feasibility of Immuno-OCT (DETOUR)

Barrett Esophagus | Colon Carcinoma | Gastrointestinal Dysplasia
Fudan University

Recruiting

The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Fudan University

Recruiting

VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Colorectal Cancer

China
Asociación para Evitar la Ceguera en México

Withdrawn

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Central Serous Chorioretinopathy

Mexico
Asociación para Evitar la Ceguera en México

Terminated

Efficacy of Retreatments With Intravitreal Bevacizumab

Age Related Macular Degeneration | Choroidal Neovascularization

Mexico
Massachusetts Eye and Ear Infirmary

Completed

Topical Avastin for Treatment of Corneal Neovascularization

Corneal Neovascularization

United States
Qilu Hospital of Shandong University
Renmin Hospital of Wuhan University; Moriggia-Pelascini Gravedona Hospital

Completed

Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)

Coronavirus Infections

China, Italy

3

Subscribe